Corrigendum to “Outbreak of adenovirus type 55 infection in Israel” [J. Clin. Virol. 78 (2016) 31–35]

Salama, Matanelle; Amitai, Ziva; Nutman, Amir; Gottesman-Yekutieli, Tamar; Sherbany, Hilda; Drori, Yaron; Mendelson, Ella; Carmeli, Yehuda; Mandelboim, Michal

doi:10.1016/j.jcv.2016.06.014

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…334 The isolates from Tibet and Sichuan displayed similar mutation patterns, suggesting a common origin. 334 AdV-55 has spread to Israel, 335 France, 336 and globally. Whole gene sequencing and phylogenetic analysis of HAdV-55 isolates from six countries (South Korea, Japan, Singapore, Egypt, Spain, the United States) during 1969 to 2018 found that recent strains share a high degree of genomic homogeneity.…”

Section: Global Epidemiologymentioning

confidence: 99%

Adenovirus: Epidemiology, Global Spread of Novel Types, and Approach to Treatment

Lynch

Kajon

2021

Semin Respir Crit Care Med

127

187

View full text Add to dashboard Cite

Adenoviruses (AdVs) are DNA viruses that typically cause mild infections involving the upper or lower respiratory tract, gastrointestinal tract, or conjunctiva. Rare manifestations of AdV infections include hemorrhagic cystitis, hepatitis, hemorrhagic colitis, pancreatitis, nephritis, or meningoencephalitis. AdV infections are more common in young children, due to lack of humoral immunity. Epidemics of AdV infection may occur in healthy children or adults in closed or crowded settings (particularly military recruits). The vast majority of cases are self-limited. However, the clinical spectrum is broad and fatalities may occur. Dissemination is more likely in patients with impaired immunity (e.g., organ transplant recipients, human immunodeficiency virus infection). Fatality rates for untreated severe AdV pneumonia or disseminated disease may exceed 50%. More than 100 genotypes and 52 serotypes of AdV have been identified and classified into seven species designated HAdV-A through -G. Different types display different tissue tropisms that correlate with clinical manifestations of infection. The predominant types circulating at a given time differ among countries or regions, and change over time. Transmission of novel strains between countries or across continents and replacement of dominant viruses by new strains may occur. Treatment of AdV infections is controversial, as prospective, randomized therapeutic trials have not been done. Cidofovir has been the drug of choice for severe AdV infections, but not all patients require treatment. Live oral vaccines are highly efficacious in reducing the risk of respiratory AdV infection and are in routine use in the military in the United States but currently are not available to civilians.

show abstract